NEW YORK, May 10, 2011 /PRNewswire-Asia-FirstCall/ --
American Oriental Bioengineering, Inc. (NYSE: AOB), ("the Company"
or "AOBO"), a pharmaceutical company dedicated to improving health
through the development, manufacture and commercialization of a
broad range of prescription and over the counter ("OTC") products,
today announced that the Company's Zhibai Dihuang Pill ("ZD Pill")
and Ciwujia Tablet ("CWJ Tablet") have been approved for sale as
traditional Chinese medicine ("TCM") in Hong Kong by Chinese Medicine Council of
Hong Kong, ("CMCHK").
Guangxi Lingfeng Pharmaceutical, ("GLP"), a wholly owned
subsidiary of AOBO, is the manufacturer of ZD Pill, which is
formulated entirely with pure natural ingredients and herbs.
The medicine is indicated for the treatment of hot flush,
night sweat, dry mouth, sore throat, etc.
Harbin Three Happiness Bioengineering ("3H"), a wholly owned
subsidiary of AOBO, is the manufacturer of CWJ Tablet, which is
formulated entirely with pure natural ingredients and herbs.
The medicine is indicated for the treatment of fatigue, poor
appetite, back pain and knee pain, and insomnia.
Mr. Tony Liu, Chairman and CEO of
AOBO, commented, "We are honored to receive the approval for sales
of additional two TCMs in Hong Kong. These newly-approved ZD
Pill and CWJ Tablet, together with our LWDH mini Ball approved in
March, are among the very few TCM products which are manufactured
in mainland China and approved for
marketing and sales in Hong
Kong."
About American Oriental Bioengineering, Inc.
American Oriental Bioengineering, Inc. is a pharmaceutical
company dedicated to improving health through the development,
manufacture and commercialization of a broad range of prescription
and over the counter products.
Safe Harbor Statement
Statements made in this press release are forward-looking and
are made pursuant to the safe harbor provisions of the Securities
Litigation Reform Act of 1995. Such statements involve risks
and uncertainties that may cause actual results to differ
materially from those set forth in these statements. The
economic, competitive, governmental, technological and other
factors identified in the Company's filings with the Securities and
Exchange Commission, may cause actual results or events to differ
materially from those described in the forward looking statements
in this press release. The Company undertakes no obligation
to publicly update or revise any forward-looking statements,
whether because of new information, future events, or
otherwise.
Contact:
|
|
ICR, LLC
|
|
Christine Duan or Ashley
Ammon
|
|
203-682-8200
|
|
|
SOURCE American Oriental Bioengineering, Inc.